Stanford Researchers Receive $5.8 Million Grant from State Stem Cell Agency

Researchers at Stanford University’s School of Medicine today received a $5.8 million grant from the California Institute for Regenerative Medicine. Michael Longaker, MD, is the principal investigator on the five-year grant, which is focused on ways to stimulate existing adult stem cells to heal damaged nerves, bone, skin and cardiac muscle.

The grant was made as part of the institute’s Early Translational Research Awards, which are meant to move promising basic stem cell research from the laboratory into the clinic. It was one of 15 grants totaling $67.7 million that were awarded during a meeting of the institute’s 29-member governing board.

“With these Early Translational grants, CIRM has taken the first step in funding translational research that will be critical for the development of future therapies,” said CIRM president Alan Trounson in a prepared statement. “These grants are an important part of CIRM’s strategy to fund the best basic research and then bring the results of that work to patients.”

Longaker, who is the deputy director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine, and his colleagues plan to continue their ongoing study of a class of protein molecules called Wnts that mediate the natural response of adult stem cells to injury. The grant received the highest score of the 15 applications approved for funding, and reviewers were noted to be “uniformly enthusiastic” about the proposal.

“This approach takes advantage of the solution that nature itself developed for repairing damaged or diseased tissues,” Longaker wrote in the grant application, noting that it also bypasses immunological and ethical hurdles to using transplanted stem cells in human therapy because it would involve stimulating a patient’s own stem cells. “When utilizing this strategy, the goal of reaching clinical trials in human patients within five years becomes realistic.”